Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | AMY2A | P04746 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MGAM | O43451 | 2/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | TYR | P14679 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24758832 | 1.00 | MAPK1 (0.41) | MAPK1AMY2AGAAALDH1A1MGAM | |
| SCHEMBL735726 | 0.87 | MAPK1 (0.47) | MAPK1ALDH1A1SLC2A1THRB | |
| SCHEMBL7687547 | 0.87 | MAPK1 (0.47) | MAPK1ALDH1A1SLC2A1THRB | |
| SCHEMBL7085221 | 0.87 | MAPK1 (0.47) | MAPK1ALDH1A1SLC2A1THRB | |
| SCHEMBL24205780 | 0.87 | MAPK1 (0.47) | MAPK1ALDH1A1SLC2A1THRB | |
| SCHEMBL6037671 | 0.87 | MAPK1 (0.47) | MAPK1ALDH1A1SLC2A1THRB | |
| SCHEMBL730123 | 0.87 | MAPK1 (0.47) | MAPK1ALDH1A1SLC2A1THRB | |
| SCHEMBL21565007 | 0.85 | AMY1A (0.41) | MAPK1ALDH1A1THRBAMY1ATYR | |
| SCHEMBL22224178 | 0.85 | TYR (0.41) | ALDH1A1THRBAMY1ATYR | |
| SCHEMBL21535992 | 0.85 | MAPK1 (0.34) | MAPK1ALDH1A1THRBAMY1ATYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017535-A1 | INHIBITORS OF ALDOSE REDUCTASE | BARCLAYS BANK PLC (GB) | 2022-01-20 | — | — | US | disclosed |
| WO-2020205846-A1 | INHIBITORS OF ALDOSE REDUCTASE | APPLIED THERAPEUTICS INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| US-20200071736-A1 | METHOD FOR THE ENZYMATIC SACCHARIFICATION OF A POLYSACCHARIDE | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017535-A1 | INHIBITORS OF ALDOSE REDUCTASE | PMM2, DPM1, BPGM | MAPK1 1805/4885AMY2A 581/4885GAA 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.